4.5 Meeting Abstract

Open Label Ustekinumab for the treatment of anti-TNFα refractory moderate-to-severe Crohn's disease: Follow up of a cohort of patients at an academic inflammatory bowel disease center

Journal

INFLAMMATORY BOWEL DISEASES
Volume 17, Issue -, Pages S13-S14

Publisher

WILEY-BLACKWELL
DOI: 10.1097/00054725-201112002-00041

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available